Myelodysplastic syndromes (MDS) constitute a group of clonal stem cell disorders distinguished by pancytopenia, ineffective haematopoiesis and a predisposition to acute myeloid leukaemia (AML) (Hellstrom‐Lindberg, [2005](#bjh13610-bib-0016){ref-type="ref"}). By contrast, the MDS subgroup refractory anaemia with ring sideroblasts (RARS) is characterized by a stable clinical course, isolated anaemia, expanded erythropoiesis and the morphological presence of ring sideroblasts (RS) (Mufti *et al*, [2008](#bjh13610-bib-0029){ref-type="ref"}). Sideroblast formation starts during early erythroid maturation, when iron accumulates in mitochondria in the form of aberrant mitochondrial ferritin (FTMT) (Cazzola *et al*, [2003](#bjh13610-bib-0005){ref-type="ref"}; Tehranchi *et al*, [2005a](#bjh13610-bib-0048){ref-type="ref"}). Somatic mutations in *SF3B1*, a core component of the RNA splicing machinery were initially found in more than 70% of RARS patients (Papaemmanuil *et al*, [2011](#bjh13610-bib-0034){ref-type="ref"}). In parallel, Yoshida *et al* ([2011](#bjh13610-bib-0056){ref-type="ref"}) reported additional mutations affecting multiple components of the RNA splicing machinery in MDS (*U2AF35, ZRSR2, SRSF2* and *SF3B1*). Of these, *SF3B1* mutations alone had a positive predictive value for disease phenotypes with ring sideroblasts of 97·7% (Malcovati *et al*, [2011](#bjh13610-bib-0025){ref-type="ref"}). Interestingly, *SF3B1* mutated samples show under‐expressed mRNA profiles with emphasis on mitochondrial pathways (Papaemmanuil *et al*, [2011](#bjh13610-bib-0034){ref-type="ref"}).

More recently we reported mutational data from a cohort of 159 morphologically well‐defined patients with RARS and refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD‐RS) and showed (81/90) 90% *SF3B1* mutations in the former category and (48/67) 72% in the latter, if patients with *TP53* mutations were removed. Moreover, no differences in survival or disease progression were observed between RARS or RCMD‐RS patients with sole *SF3B1* mutations, and those with additional mutations in the two main other genes *TET2* and *DNMT3A*. *SF3B1* wild type patients showed a varying mutational pattern; 10/33 (33%) had other splice factor mutations (*SRSF2, U2AF1, ZRSR2*), and 11/30 (37%) had epigenetic mutations (*TET2, DNMT3A, ASXL1*) (Malcovati *et al*, [2015](#bjh13610-bib-0026){ref-type="ref"}).

We and others have shown that the markedly under‐expressed iron transporter gene *ABCB7* is an important mediator of the RARS phenotype (Nikpour *et al*, [2013](#bjh13610-bib-0032){ref-type="ref"}; Dolatshad *et al*, [2015](#bjh13610-bib-0009){ref-type="ref"}).

Albeit these findings indicate that abnormal RNA is a common consequence of *SF3B1* mutations, downstream targets associated with the development of ineffective erythropoiesis have not yet been identified, nor the maturation phase during which erythropoiesis is affected. Splicing patterns and gene expression undergo major changes during normal cell differentiation (An *et al*, [2014](#bjh13610-bib-0002){ref-type="ref"}; Cheng *et al*, [2014](#bjh13610-bib-0007){ref-type="ref"}; Pimentel *et al*, [2014](#bjh13610-bib-0040){ref-type="ref"}) making longitudinal studies during erythroid maturation highly relevant (Nikpour *et al*, [2010](#bjh13610-bib-0031){ref-type="ref"}, [2013](#bjh13610-bib-0032){ref-type="ref"}). We speculated that *SF3B1* mutations could alter splicing and expression patterns of genes essential for normal erythroid maturation.

Hereby, we report altered splicing of genes involved in haemoglobin synthesis, and a failure to up‐regulate essential cell growth signalling pathways during erythroid differentiation. Importantly, we present evidence that *SF3B1* mutation does not confer a growth or maturation disadvantage to erythroid cells until terminal maturation into reticulocytes, providing a novel understanding about the mechanism for anaemia in *SF3B1* mutated RARS.

Material and methods {#bjh13610-sec-0002}
====================

Sample collection, erythroid and myeloid cell cultures {#bjh13610-sec-0003}
------------------------------------------------------

Patients with MDS, \<5% marrow blasts, and \>15% ring sideroblasts \[RARS, RCMD‐RS, RARS associated with marked thrombocytosis (RARS‐T)\] were diagnosed using World Health Organization (WHO) criteria and a multi‐professional conference approach (Howe *et al*, [2004](#bjh13610-bib-0018){ref-type="ref"}; Vardiman *et al*, [2009](#bjh13610-bib-0051){ref-type="ref"}). The study was approved by the Ethics Research Committee at Karolinska Institutet (2010/427‐31/1 and 2011/1257‐31) and informed consent was obtained from patients and healthy donors. RARS and normal CD34^+^ cells from bone marrow (BM) were cultured for 14 days, as previously described in detail (Tehranchi *et al*, [2003](#bjh13610-bib-0047){ref-type="ref"}; Pellagatti *et al*, [2007](#bjh13610-bib-0038){ref-type="ref"}; Nikpour *et al*, [2010](#bjh13610-bib-0031){ref-type="ref"}, [2013](#bjh13610-bib-0032){ref-type="ref"}). In order to obtain fresh mature erythroid progenitors, Glycophorin A (GPA) selection (Miltenyi Biotech, Bergisch Gladbach, Germany) was performed on freshly isolated mononuclear cells (MNCs) with a purity of \>95% as previously reported (Tehranchi *et al*, [2003](#bjh13610-bib-0047){ref-type="ref"}, [2005a](#bjh13610-bib-0048){ref-type="ref"}; Nikpour *et al*, [2010](#bjh13610-bib-0031){ref-type="ref"}). To induce myeloid differentiation, cells were treated with hydrocortisone (0·01M, StemCell Technology, Grenoble, France) and granulocyte colony‐stimulating factor (20 ng/ml, PeproTech, Rocky Hill, NJ, USA) at day 7 in Myelocult medium. Myeloid purity was evaluated by flow cytometry (CD66b \>90%) at day 14 of culture. Reticulocytes were isolated from peripheral blood (PB) of 5 patients maintaining stable anaemia without treatment or transfusions, as described by Petruzzelli *et al* ([2009](#bjh13610-bib-0039){ref-type="ref"}). Genomic DNA was extracted from isolated CD34^+^, CD34^−^, PB CD3^+^ cells and granulocytes using GenElute^™^ Mammalian DNA Miniprep Kit (Sigma Aldrich, St. Louis, MO, USA) and total RNA using Trizol (Invitrogen, Paisley, UK).

Targeted sequencing of candidate genes {#bjh13610-sec-0004}
--------------------------------------

Patient\'s DNA from PB granulocytes or BM MNCs was screened for recurrently mutated genes in myeloid disorders either by SureSelect (Agilent Technologies, Berkshire, UK) as previously reported (Papaemmanuil *et al*, [2013](#bjh13610-bib-0036){ref-type="ref"}) or using high‐throughput sequencing by Haloplex^™^ target enrichment technology (Agilent Technologies). Haloplex^™^ target enrichment kit G9901A/B was designed for 42 genes (Table SI) using Halodesign wizard available via Agilent (<http://www.halogenomics.com>). For details on sequencing data analysis, see Supporting Information.

RNA Sequencing {#bjh13610-sec-0005}
--------------

Total RNA (between 177 ng and 3 μg) from BM CD34^+^ cells of 3 patients (MDS 12, 13 and 14) and 3 normal bone marrows (NBM) during erythroid differentiation was depleted of ribosomal RNA using RiboMinus Eukaryote kit for RNA‐Seq (LifeTechnologies, Carlsbad, CA, USA). Strand‐specific libraries were constructed using SOLiD^™^ Total RNA‐Seq Kit according to the manufacturer\'s instructions (LifeTechnologies). For details on libraries sequencing, see Supporting Information. Samples were sequenced as single‐reads on the SOLiD 5500 Wildfire system. An average of approximately 246 million reads were generated per sample and out of these, an average of 141 million reads were mapped to the human reference genome (hg19). For differential expression and splicing analysis, Cufflinks version 2·1·1 (<http://cole-trapnell-lab.github.io/cufflinks/>) was used. The alignment of sequence reads in the same sample type were assembled into transcripts by Cufflinks, using RefSeq transcripts as reference.

Assembled transcripts were grouped by Cuffmerge and the merged transcripts assembly was compared with the reference RefSeq transcripts by Cuffcompare using default setting (Trapnell *et al*, [2012](#bjh13610-bib-0050){ref-type="ref"}). Relative abundance (fragments per kilobase of exon per million of fragments mapped, FPKM) was calculated. Differential expression and exon‐usage were estimated by Cuffdiff using default setting (Trapnell *et al*, [2012](#bjh13610-bib-0050){ref-type="ref"}). An arbitrary cutoff of FPKM\>1 was applied, thus genes were considered as expressed if FPKM\>1.

Gene set enrichment analysis {#bjh13610-sec-0006}
----------------------------

The input data for the Gene Set Enrichment Analysis (GSEA) (Subramanian *et al*, [2005](#bjh13610-bib-0044){ref-type="ref"}) were complete lists of genes differentially expressed between RARS and NBM at day 0 and at day 4. The lists were pre‐ranked according to the log~10~ (*P* value*)* of each gene. Probesets (12038 annotated transcripts at day 0 and 9186 at day 4) were collapsed into gene symbol. Inclusion gene set size was set between 15 and 500 and the phenotype was permutated 1000 times. Gene sets that met a false discovery rate (FDR) less than 0·05 were considered. For this analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG; Kanehisa & Goto, [2000](#bjh13610-bib-0020){ref-type="ref"}) was used as gene matrix.

Statistical analysis {#bjh13610-sec-0007}
--------------------

Statistical analysis was performed using GraphPad Prism 6 software (La Jolla, CA, USA). Gene expression and splicing isoform validation data by quantiative polymerase chain reaction (qPCR) were analysed using the Comparative Ct method according to User Bulletin \#2 (Applied Biosystems, Foster City, CA, USA). Due to small sample size and skewed distribution, gene expression in patient samples and healthy controls was compared using the Mann--Whitney *U* test. Statistical analysis for allele burden assessment during erythroid maturation was performed using paired Student *t*‐test.

Taqman low density array (TLDA) {#bjh13610-sec-0008}
-------------------------------

Gene expression profiles were investigated using TDLA. BM CD34^+^ cells at day 0 and 4 from 7 RARS and 4 NBM erythroid cultures were run in triplicate. Each TLDA card allowed simultaneous quantification of 61 target genes per sample. TLDA data was analysed using Comparative Ct method according to User Bulletin \#2 (Applied Biosystems). For details on TLDA analysis see Supporting Information. Principle Component Analysis (PCA) was performed using R statistics package "prcomp" (<http://www.r-project.org/>).

Pyrosequencing {#bjh13610-sec-0009}
--------------

Pyrosequencing (PyroMark Q24 system, Qiagen, Düsseldorf, Germany) was applied to follow the fate of the *SF3B1* clone during erythroid differentiation. DNA from cultured BM CD34^+^, freshly isolated BM MNCs and GPA^+^ cells of RARS patients was used with DNA from NBM, as wild type control. cDNA synthetized using High Capacity cDNA Reverse Transcription kit (Applied Biosystems) was used to assess allele burden in reticulocytes. Mutation‐specific assays (Table SII) were designed using PyroMark assay design software and performed according to the PyroMark Q24 user manual (Qiagen).

Results {#bjh13610-sec-0010}
=======

Patients {#bjh13610-sec-0011}
--------

Eighteen patients with *SF3B1* mutations and 2 *SF3B1* wild type patients had material available for this study. Median age was 74 years (49--91 years) and final diagnosis was established at a multi‐professional conference. Clinical and morphological characteristics as well as the molecular profile of the cohort are presented in Table SIII. Several of the samples had additional recurrent mutations, such as *JAK2, TET2* and *DNMT3A* (Papaemmanuil *et al*, [2013](#bjh13610-bib-0036){ref-type="ref"}).

Marked differences in gene expression during early erythroid differentiation {#bjh13610-sec-0012}
----------------------------------------------------------------------------

To examine if splicing factor mutations may contribute to dissimilarities between *SF3B1* mutated RARS and NBM, we assessed loci‐based differential expressions by RNA sequencing during early erythroid differentiation at two time‐points (day 0 and 4). We detected 5292 loci differentially expressed (FDR\<5% and FPKM\>1) at day 0 and 2329 loci at day 4 (Fig [1](#bjh13610-fig-0001){ref-type="fig"}A--B). Next, we investigated the genes showing different development of expression between RARS and NBM over the 4 days in culture. We observed marked alterations during RARS differentiation (Figure [1](#bjh13610-fig-0001){ref-type="fig"}C‐D). In particular, 953 genes were significantly (FDR\<5% and fold change of ≥1·5) up‐regulated during normal erythropoiesis, compared to only 333 genes in the RARS cultures. Hence, the expression of 710 genes failed to increase during RARS erythropoiesis. The functional annotation of these genes was analysed using DAVID (Database for Annotation, Visualization and Integrated Discovery) (Huang da *et al*, [2009](#bjh13610-bib-0019){ref-type="ref"}) and the most enriched functional clusters were mainly involved in the cell cycle process including mitosis, spindle organization and chromosome segregation (Table SIV). Furthermore, we identified 511 down‐regulated genes during normal erythropoiesis compared to 893 in RARS, i.e. 222 genes failed to decrease during RARS erythropoiesis. Interestingly, the functional annotation of these 222 genes failed to identify any significant enriched clusters (Table SV). Overall, these data suggest that *SF3B1* mutated RARS is associated with decreased gene expression resulting from a failure to up‐regulate genes regulating the cell cycle process during early erythroid differentiation.

![RNA sequencing reveals gene expression differences between RARS and NBM during early differentiation. Bone marrow CD34^+^ cells were isolated from 3 RARS patients (MDS12, 13, 14) and 3 NBM controls and cultured in the erythroblast system for 4 days. Samples for RNA were taken at day 0 and day 4. (A) Volcano plots show 5292 loci (both annotated and un‐annotated) up‐regulated at day 0 and (B) 2329 down‐regulated at day 4 (FDR\<5% and FPKM\>1). Each graph is constructed by plotting the negative log of the *P*‐value (*Y*‐axis) *versus* the log of the fold change (1·5‐fold change) (*X*‐axis) between RARS and NBM. Red circles denote statistical significance (FDR \<5%) defined loci by Cufflinks. (C--D) Venn diagrams display distributions of differentially expressed transcripts between NBM and RARS during early differentiation (0--4 days) based on FDR \<5% and a fold change of 1·5. Only annotated transcripts were included for these diagrams. During erythropoiesis, 333 (90 + 243) genes were up‐regulated in RARS and 953 (710 + 243) genes in NBM. 243 genes were up‐regulated both in RARS and NBM. During early RARS erythropoiesis, 893 genes were down‐regulated, compared to 511 in NBM. A total of 289 genes were down‐regulated in both RARS and NBM. (E) Gene Set Enrichment Analysis (GSEA) of RARS compared to NBM at day 0 reveals positive enrichment plots for canonical pathways of RARS such as spliceosome, oxidative phosphorylation, ribosome and proteasome. (F) Conversely, at day 0 the GSEA analysis shows a negative enrichment of signalling pathways such as: WNT, MAPK and mTOR and ABC transporters. Each vertical stripe represents the rank of a gene within the gene set among all (12038 at day 0 and 9186 at day 4). Name of the gene set is shown to the left, and q value to the right. FPKM, fragments per kilobase of exon per million of fragments mapped; FDR, false discovery rate; MDS, myelodysplastic syndrome; RARS, refractory anaemia with ring sideroblasts; NBM, normal bone marrow; dw, down‐regulated; KEGG, Kyoto Encyclopedia of Genes and Genomes.](BJH-171-478-g001){#bjh13610-fig-0001}

Gene Set Enrichment Analysis identifies the key pathways of RARS pathogenesis {#bjh13610-sec-0013}
-----------------------------------------------------------------------------

We used GSEA (Subramanian *et al*, [2005](#bjh13610-bib-0044){ref-type="ref"}) to identify biological pathways that showed coordinated up‐regulation or down‐regulation in RARS compared to NBM. With a FDR of less than 0·05, we identified 14 gene sets (out of 151 screened) positively enriched, and 12 gene sets negatively enriched at day 0, whereas 18 and 1 gene sets showed a positive and negative enrichment at day 4, respectively. GSEA based on KEGG database revealed an up‐regulation at both time points for canonical pathways of RARS pathogenesis, such as spliceosome, but also of the oxidative phosphorylation, ribosome and proteasome pathways (Fig [1](#bjh13610-fig-0001){ref-type="fig"}E). The oxidative phosphorylation enrichment, a possible consequence of the mitochondrial ferritin accumulation or compromised mitochondrial respiratory chain activity, mainly included genes encoding subunits of the Complex I (NADH dehydrogenase) and V (ATP synthase) of the respiratory chain. Ribosomal abnormalities have been previously described in MDS pathophysiology in conjunction with deletion of 5q (Ebert *et al*, [2008](#bjh13610-bib-0011){ref-type="ref"}). Studies have shown that haploinsufficiency of ribosomal protein genes causes selective activation of TP53 (p53) in human erythroid progenitor cells (Dutt *et al*, [2011](#bjh13610-bib-0010){ref-type="ref"}). The positive enrichment of the proteasome has been reported only in high risk MDS, and often associated with apoptosis after treatment with proteasome inhibitors (Alimena *et al*, [2011](#bjh13610-bib-0001){ref-type="ref"}; Liesveld *et al*, [2011](#bjh13610-bib-0024){ref-type="ref"}). Conversely, GSEA showed down‐regulation of WNT, MAPK and mTOR signalling pathways involved in apoptosis and transcription regulation, as well as ATP‐binding cassette mitochondrial transporters (ABC transporters) (Figure [1](#bjh13610-fig-0001){ref-type="fig"}F). The latter gene set included *ABCB7*, a key mediator of the RARS phenotype (Nikpour *et al*, [2013](#bjh13610-bib-0032){ref-type="ref"}) involved in iron metabolism and transport of Fe/S protein precursors.

RARS progenitors up‐regulate genes involved in haemoglobin synthesis {#bjh13610-sec-0014}
--------------------------------------------------------------------

Compared to NBM, several of the top 20 up‐regulated genes in RARS at day 0 were involved in the haem and haemoglobin synthesis pathway (*HBM, HBA2, ALAS2, HBA1*) (Table [1](#bjh13610-tbl-0001){ref-type="table-wrap"}). In particular, *HBA1* and *HBA2* encode the α‐globin protein and both genes are located close together in the α‐globin locus on chromosome 16. Mutations of these genes are the most common cause of α‐thalassemia (Murru *et al*, [1991](#bjh13610-bib-0030){ref-type="ref"}); however, *HBA2* was also reported down‐regulated in differentiating erythroblasts from MDS patients with del(5q) after treatment with lenalidomide (Pellagatti *et al*, [2007](#bjh13610-bib-0038){ref-type="ref"}). Interestingly, *HBM* was initially identified as a pseudogene and later reported as part of the transcriptome profile of human reticulocytes and transcribed in a highly regulated pattern in erythroid cells with its maximal expression during the erythroblast terminal differentiation (Goh *et al*, [2005](#bjh13610-bib-0012){ref-type="ref"}). We also confirmed a strong up‐regulation of *ALAS2* previously reported in RARS (Pellagatti *et al*, [2006](#bjh13610-bib-0037){ref-type="ref"}). The expression levels of *ALAS2, HBM*,*HBA2* and *HBA1* were similar in *SF3B1* mutated (*n* = 6) and wild type (*n* = 2) patients (data not shown).

###### 

Top 20 up and down‐regulated genes between RARS and normal bone marrow at day 0

  Gene                                               Locus                       FPKM NBM   FPKM MDS   log2(MDS/NBM)   FDR     Function
  -------------------------------------------------- --------------------------- ---------- ---------- --------------- ------- -----------------------------------------------------------------------------------
  \(A\) Up‐regulated genes                                                                                                     
  *XIST*                                             chrX:73012039‐73072588      0·026      54·783     11·032          0·004   X‐Inactivation that silences one of the pair of X chromosomes
  [a](#bjh13610-note-0002){ref-type="fn"} *HBM*      chr16:215972‐216767         0·316      170·276    9·075           0·016   Haemoglobin μ, iron ion binding and oxygen binding
  *FCGBP*                                            chr19:40353962‐40440533     0·064      17·509     8·095           0·004   Maintenance of the mucosal structure
  *TIMD4*                                            chr5:156345573‐156345938    0·996      237·879    7·900           0·004   Regulation of T‐cell proliferation
  *HBA2*                                             chr16:222845‐223709         1·300      301·970    7·859           0·004   Haemoglobin α‐2, ion and oxygen biniding
  *ALAS2*                                            chrX:55035487‐55057497      0·415      87·171     7·716           0·004   Haem biosynthetic pathway
  *HBA1*                                             chr16:226643‐228694         1·097      222·552    7·665           0·004   Haemoglobin α‐1, release of oxygen by erythrocytes and scavenging of haem
  *HRH1*                                             chr3:11178778‐11304939      0·040      6·833      7·416           0·004   Histamine receptor activity
  [a](#bjh13610-note-0002){ref-type="fn"} *VCAM1*    chr1:101204878‐101205214    0·695      107·010    7·267           0·007   Integrin binding and cell adhesion molecule binding
  *EDNRB*                                            chr13:78469615‐78549664     0·102      15·320     7·237           0·004   Peptide hormone binding and endothelin receptor activity
  *ATP6V0D2*                                         chr8:87111077‐87166454      0·112      16·466     7·199           0·004   Providing energy required for transport processes in the vacuolar system
  *CERS3*                                            chr15:100940599‐101084925   0·022      3·160      7·181           0·034   Sphingosine N‐acyltransferase activity and transcription factor activity
  [a](#bjh13610-note-0002){ref-type="fn"} *CD5L*     chr1:157800703‐157811634    3·677      782·091    7·172           0·004   Scavenger receptor activity, possible role as an inhibitor of apoptosis
  *RND3*                                             chr2:151324709‐151344221    0·180      25·674     7·154           0·004   GTP binding and GTPase activity
  *LILRB5*                                           chr19:54753206‐54753669     0·294      41·095     7·127           0·049   Transmembrane signaling receptor activity
  *LYVE1*                                            chr11:10562786‐10715535     0·480      60·302     6·972           0·007   Autocrine regulation of cell growth
  *CCL18*                                            chr17:34399750‐34402443     0·033      4·096      6·954           0·035   Immunoregulation and inflammation, chemotactic activity for T cells
  *MSR1*                                             chr8:15965386‐16050319      0·444      54·932     6·951           0·004   Macrophge scavenger receptor activity
  *SLC4A1*                                           chr17:42325757‐42345502     0·250      30·605     6·937           0·004   Uptake of carbon dioxide and release of oxygen by erythrocytes
  *CCL8*                                             chr17:32646065‐32648421     0·295      34·326     6·862           0·004   Protein kinase activity and chemokine activity
  \(B\) Down‐regulated genes                                                                                                   
  [a](#bjh13610-note-0002){ref-type="fn"} *ULK4P3*   chr15:32698800‐32727250     4·611      0·449      −3·360          0·004   *ULK4* pseudogene 3, unknown function
  *WWOX*                                             chr16:78760629‐78761056     5·973      0·834      −2·840          0·007   Oxidoreductase that acts as a tumor suppressor and plays a role in apoptosis
  *CAMK1D*                                           chr10:12466821‐12467259     5·474      0·852      −2·684          0·007   Calcium/calmodulin‐dependent kinase, role in apoptosis of erythroleukemia cells
  *PRKCE*                                            chr2:45997530‐45997967      3·401      0·536      −2·665          0·029   Protein kinase activity
  [a](#bjh13610-note-0002){ref-type="fn"} *RNF220*   chr1:45030902‐45031276      6·598      1·154      −2·516          0·007   Ubiquitination and proteasomal degradation of SIN3B
  *PRKCH*                                            chr14:61933032‐61933557     2·599      0·457      −2·509          0·037   Regulation of cell differentiation in keratinocytes and pre‐B cell receptor
  *PLCB1*                                            chr20:8291278‐8291669       3·810      0·736      −2·371          0·041   Hydrolysis of phospholipids into fatty acids
  *GNLY*                                             chr2:85921413‐85925977      2·085      0·419      −2·315          0·004   Antimicrobial activity
  *BCR*                                              chr22:23563521‐23563723     33·971     6·880      −2·304          0·018   GTPase and serine/threonine kinase activity
  *LRIG1*                                            chr3:66488799‐66489239      3·708      0·767      −2·273          0·048   Negative regulator of signaling by receptor tyrosine kinases
  *INPP5A*                                           chr10:134526579‐134527222   1·983      0·424      −2·225          0·047   Inositol‐polyphosphate 5‐phosphatase activity
  *PRKG1*                                            chr10:53142352‐53143618     1·053      0·242      −2·123          0·021   Mediator of the nitric oxide (NO)/cGMP signaling pathway
  *AOX2P*                                            chr2:201560443‐201660451    32·892     7·630      −2·108          0·004   Aldehyde oxidase 2, pseudogene affiliated with the lncRNA class
  *SLC16A14*                                         chr2:230899676‐230933816    1·483      0·347      −2·094          0·028   Proton‐linked monocarboxylate transporter
  *BRF1*                                             chr14:105726207‐105726823   4·543      1·124      −2·015          0·004   RNA Polymerase III Transcription Initiation and Transcription of tRNA
  *FOXP1*                                            chr3:71532609‐71532947      8·119      2·079      −1·965          0·018   Transcriptional repressor, essential transcriptional regulator of B‐cell
  *TMEM163*                                          chr2:135360910‐135361983    1·279      0·329      −1·957          0·016   Zinc ion binding
  *NCK2*                                             chr2:106380446‐106380910    6·308      1·720      −1·874          0·012   Regulation of receptor protein tyrosine kinases and cytoskeletal adaptor activity
  *FHIT*                                             chr3:59928983‐59929714      2·466      0·675      −1·870          0·031   Pyrimidine metabolism and inducer of apoptosis via SRC and AKT1 signaling
  *STK32B*                                           chr4:5202129‐5202796        2·610      0·724      −1·851          0·028   Serine/threonine kinase activity and metal ion binding

FPKM, fragments per kilobase of exon per million of fragments mapped; FDR, false discovery rate; MDS, myelodysplastic syndrome; RARS, refractory anaemia with ring sideroblasts; NBM, normal bone marrow.

Genes commonly deregulated both at day 0 and day 4. Notably, the up‐regulation of *TIMD4, ALAS2, CD5L, LYVE1, CCL18* and *MSR1* detected by RNA sequencing was confirmed by Taqman Low Density Array.
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In contrast to the up‐regulation of haemoglobin synthesis related genes, we found down‐regulation of tumour suppressors and apoptosis‐promoting genes, such as *FHIT* and *CAMK1D* (Table [1](#bjh13610-tbl-0001){ref-type="table-wrap"}) suggesting a mechanism for RARS progenitors to survive until a more mature stage of differentiation and a potential contribution to erythroid hyperplasia.

We validated the expression of 5 of the top 20 up‐regulated and down‐regulated in 3 NBM and 6 RARS using qPCR. Indeed, *ALAS2, HBM* and *SLC4A1* were significantly up‐regulated compared to NBM (*P = *0·023 for all tested genes) (Fig [2](#bjh13610-fig-0002){ref-type="fig"}A). In contrast, *CAMK1D* and *FHIT* were down‐regulated versus NBM (*P *=* *0·047, *P *=* *0·023 respectively) (Fig [2](#bjh13610-fig-0002){ref-type="fig"}B).

![Validation of gene expression profiles. Quantiative polymerase chain reaction analysis of RARS (*n* = 6) *versus* NBM (*n* = 3) confirms (A) the up‐regulation of *ALAS2, HBM* and *SLC4A1* and (B) the down‐regulation of *CAMK1D* and *FHIT* observed in the RNA sequencing. Level of statistical significance was assessed using Mann‐Whitney test (\**P* \<0.05).](BJH-171-478-g002){#bjh13610-fig-0002}

Finally, at day 4 of erythroid culture, we found up‐regulation of genes with a scavenger receptor role, such as *CD5L* and *CD163*. *CD163* is an haemoglobin scavenger receptor that may protect from free haemoglobin‐mediated oxidative damage (Moestrup & Moller, [2004](#bjh13610-bib-0028){ref-type="ref"}) (Table SVI).

SF3B1 mutated RARS progenitors show alternative splicing of genes involved in haemoglobin synthesis {#bjh13610-sec-0015}
---------------------------------------------------------------------------------------------------

Alternative splicing can generate multiple mRNA isoforms and proteins from a single locus. Changes in the splicing process are important for cell differentiation and may contribute to the difference in gene expression between RARS and NBM (Pellagatti *et al*, [2006](#bjh13610-bib-0037){ref-type="ref"}; Nikpour *et al*, [2010](#bjh13610-bib-0031){ref-type="ref"}). RNA sequencing revealed 18 mis‐spliced genes at day 0, none of which had been reported before to have a role in MDS (Table SVII). By contrast, 2 genes (*ANKHD1* and *TMEM14C*) showed altered splicing at day 4 and only *TMEM14C* was differentially spliced at both time points. Interestingly, the function of *TMEM14C* and *TFCP2* is closely related to mitochondria and to haem biosynthesis in particular (Yien *et al*, [2014](#bjh13610-bib-0055){ref-type="ref"}). *TMEM14C* is a mitochondrial transporter and the knockdown of this gene in zebrafish led to profound anaemia without affecting erythroid lineage specification (Nilsson *et al*, [2009](#bjh13610-bib-0033){ref-type="ref"}). Two isoforms of *TMEM14C* were detected in our material: TCONS_00409015 was 3·5 times up‐regulated in RARS compared to NBM, while the expression of TCONS_00409016 was significantly down‐regulated in RARS versus NBM (Fig [3](#bjh13610-fig-0003){ref-type="fig"}A). Notably, the shorter isoform TCONS_00409016 differs from the other variant in that it has 14 bases (328‐341) missing in the 5′UTR (Figure [3](#bjh13610-fig-0003){ref-type="fig"}B). An internal ribosome entry site (IRES), a translation initiation alternative to the conventional 5′‐cap translation mechanism, was predicted by UTRdb (Grillo *et al*, [2010](#bjh13610-bib-0013){ref-type="ref"}) at position 295‐385 of *TMEM14C*.

![Quantification of *TMEM14C* and *TFCP2* transcript splice variants in RARS (*n* = 5) *versus* NBM (*n* = 3). (A) RNA sequencing based analysis shows differential expression of different TCONS corresponding to *TMEM14C* and *TFCP2*. (B--C) Top panels show browser view of the exon‐intron structure for *TMEM14C* and *TFCP2*, respectively (the red square indicating the differential splicing site). Bottom panel, quantiative polymerase chain reaction detected fold change of the TCONS is shown. (B) In NBM, the *TMEM14C* isoform TCONS15 was significantly up‐regulated compared to RARS (*P = *0·035) while the shorter isoform TCONS16 (missing 14 bp in the 5′UTR) was decreased 1·3 fold in RARS versus NBM (*P = *0·035). (C) The levels of *TFCP2* transcripts containing exon 6 were significantly lower (*P = *0·035) in RARS than NBM, while the isoform TCONS40 was higher expressed in RARS compared to NBM. Delta CT were normalized using *GAPDH* as reference gene, NBM samples (*n* = 3) were used as calibrator. Level of statistical significance was assessed using Mann--Whitney test (\**P *\<* *0·05). FPKM, fragments per kilobase of exon per million of fragments mapped; FDR, false discovery rate; MDS, myelodysplastic syndrome; RARS, refractory anaemia with ring sideroblasts; NBM, normal bone marrow.](BJH-171-478-g003){#bjh13610-fig-0003}

*TFCP2* is a transcription factor that activates the transcription of the α‐globin gene, thus regulating the erythroid gene expression (Kang *et al*, [2005](#bjh13610-bib-0021){ref-type="ref"}). Among the 3 isoforms found (Fig [3](#bjh13610-fig-0003){ref-type="fig"}A), TCONS_0012739 showed a skipping of 153 bases (1286--1438) in the sixth exon of the mRNA corresponding to the CP2 DNA binding domain that binds the--α‐globin promoter. CP2 is a major factor in the regulation of globin expression in human and mouse erythroid cells, and CP2 binding to the promoter is essential for the enhanced transcription of globin genes in erythroid differentiation (Chae & Kim, [2003](#bjh13610-bib-0006){ref-type="ref"}).

We selected *TMEM14C* and *TFCP2* for further splice‐form validation due to their potential relevance to the disease phenotype. We measured the abundance of each splicing isoform in 3 NBM and 5 RARS patients using qPCR. Primers specificity and amplicons identity were validated using Sanger Sequencing (Table SVIII).

In regard to *TMEM14C*, TCONS_00409015 (referred as TCONS15 in the figure) was significantly up‐regulated in RARS compared to NBM (*P *=* *0·035). By contrast TCONS_00409016 (referred as TCONS16 in the figure) was decreased 1·3‐fold in RARS versus NBM (*P *=* *0·035) (Figure [3](#bjh13610-fig-0003){ref-type="fig"}B).

For *TFCP2* we measured the abundance of transcripts containing exon 6 and interestingly, we observed a 1·3 fold‐decrease in RARS *versus* NBM (*P *=* *0·035); whereas the expression of TCONS00112740 (referred as TCONS40 in the figure, Taqman probe: Hs_01117310_m1) showed the same trend as in the RNA Sequencing, however inter‐patient variation was high and the comparison was not statistically significant (Fig [3](#bjh13610-fig-0003){ref-type="fig"}C).

In order to assess the impact of *SF3B1* mutations on these erythroid‐related genes, we measured the expression of *TMEM14C* and *TFCP2* splice variants in two additional *SF3B1* wild type patients analysed by exome sequencing (Table SIII, data from exome sequencing not shown). With the caveat of the statistical limitation, we observed that *TMEM14C* TCONS15 was significantly down‐regulated in *SF3B1* wild type compared to mutated patients (*P = *0·001) (Fig. S1). This indicates that *SF3B1* mutations might contribute to ineffective erythropoiesis by altering the splicing of genes involved in haemoglobin syntesis. Functional studies will be needed to establish how these genes cooperate in generating the RARS phenotype.

The additional 16 mis‐spliced genes (Table SVII) were related to various functions, such as DNA replication (*DUT*), MAPK signalling pathway (*MBIP*), transcription regulation (*ZNF518B, EIF2B4, TGIF2*), blood coagulation (*PROCR*), intracellular trafficking and energy metabolism (*ACBD3, SNX3, CYP2S1, NUDT7*). Of note, the coverage of *ABCB7* for which we previously showed altered exon usage at day 7 and 14 of erythroid culture was suboptimal for analysis of splicing patterns. Taken together, these results show that the inappropriate splicing seems to be closely associated not only with aberrant expression, but also with a dys‐regulation of downstream target genes important for erythroid differentiation.

TLDA analysis confirms data from RNA sequencing and highlights a clear heterogeneity of the RARS cohort {#bjh13610-sec-0016}
-------------------------------------------------------------------------------------------------------

We then used a gene expression approach to study selected genes during early erythroid differentiation (day 0--4) from 7 RARS patients and 4 NBM. The assay included 61 genes that were selected based on pilot RNA sequencing results (data not shown) and previous publications (Pellagatti *et al*, [2006](#bjh13610-bib-0037){ref-type="ref"}; Nikpour *et al*, [2010](#bjh13610-bib-0031){ref-type="ref"}). TLDA data revealed 20 genes differentially expressed at day 0 and 17 genes at day 4 (*P *\< 0·05) between RARS and NBM (Table SIX). The up‐regulation of *TIMD4, ALAS2, CD5L LYVE1, CCL18* and *MSR1,* observed in the RNA sequencing (Table [1](#bjh13610-tbl-0001){ref-type="table-wrap"}), and *CXCL12* (Table SVI) was validated and confirmed by TLDA (Table SIX).

Importantly, several of the genes selected for this assay (*ABCB7, ALAS2, APOE, HBB, MFN2, SEPP1*) were differentially expressed between RARS and NBM and involved in the defence against oxidative stress (Miyata & Smith, [1996](#bjh13610-bib-0027){ref-type="ref"}; Saito *et al*, [1999](#bjh13610-bib-0041){ref-type="ref"}; Shen *et al*, [2007](#bjh13610-bib-0042){ref-type="ref"}; Liesa *et al*, [2012](#bjh13610-bib-0023){ref-type="ref"}; Khechaduri *et al*, [2013](#bjh13610-bib-0022){ref-type="ref"}). These data corroborate with the up‐regulation of the oxidative phosphorylation pathway observed in the GSEA and suggest that RARS progenitors may be challenged by oxidative stress at an early phase of differentiation.

Principle Component Analysis was performed to identify patterns and variance in the gene expression data obtained by TLDA, which included more RARS patients than in the RNA sequencing analysis. The RARS population showed a heterogeneity at both time points, while NBMs were much more uniform in gene expression, especially at day 0. All samples were *SF3B1* mutated (Table SI) and clustered independently from the amino acid substitutions (Fig [4](#bjh13610-fig-0004){ref-type="fig"}A--B). Furthermore, another PCA highlighted the target genes that contribute to distinguish NBM from RARS both at day 0 (Fig [4](#bjh13610-fig-0004){ref-type="fig"}C) and day 4 (Fig [4](#bjh13610-fig-0004){ref-type="fig"}D) which include *SEPP1, APOE, HBB and ALAS2*.

![The RARS cohort is heterogeneous and shows defective terminal maturation into erythrocytes. RARS patients (*n* = 7) and NBM (*n* = 4) were analysed at day 0 and 4 of erythroid differentiation by Taqman Low Density Array. (A) Principle Component Analysis (PCA) shows a marked heterogeneity in the gene expression of RARS samples (MDS 1, 4, 6, 8, 9, 10, 11) compared to only a minimal inter‐individual variation in the NBM population (NBM 16, 18, 19, 20) both at day 0 (B) and at day 4. (C) Genes that contribute to distinguish NBM from RARS are displayed at day 0 (D) and day 4. (E) *SF3B1* allele burden was quantified by pyrosequencing at different time points in 5 RARS samples cultured in erythroblast system (Ery). Two patients (MDS 8 and MDS 11) were also cultured in a myeloid culture system (Mye) between days 7--14. Allele burden was stable (± 10%) both during erythroid and myeloid differentiation. (F) *SF3B1* allele burden of different cell fractions: BM CD34^+^, cultured erythroblasts at day 14, GPA^+^ and reticulocytes from RARS patients (*n* = 4). There is a 1·5‐fold decrease of the allele burden in the RARS reticulocytes compared to CD34^+^ cells (*P = *0·017) and erythroblast at day 14 (*P *=* *0·033) in addition to a 1·4‐fold decrease when comparing to GPA^+^ cells (*P *=* *0·011). Level of statistical significance was assessed using paired Student *t*‐test (\**P *\<* *0·05). MDS, myelodysplastic syndrome; RARS, refractory anaemia with ring sideroblasts; NBM, normal bone marrow](BJH-171-478-g004){#bjh13610-fig-0004}

Selection against SF3B1 occurs first during terminal maturation into erythrocytes {#bjh13610-sec-0017}
---------------------------------------------------------------------------------

Mechanisms behind the low reticulocyte count and surviving erythrocytes in RARS have, to our knowledge, not been studied. To test whether *SF3B1* mutated erythroid progenitors have a growth disadvantage compared to *SF3B1* wildtype cells, we analysed the allele burden of *SF3B1* (Table SII) in RARS samples during erythroid differentiation (*n* = 5) (days 0, 4, 7, 11 and 14) (Nikpour *et al*, [2010](#bjh13610-bib-0031){ref-type="ref"}, [2013](#bjh13610-bib-0032){ref-type="ref"}), two of which were also exposed to myeloid maturation. For these experiments we utilized samples from *SF3B1* mutated RARS without need for transfusions or growth factor treatment.

Interestingly, the *SF3B1* allele burden was stable (± 10%) during both erythroid and myeloid differentiation (Fig [4](#bjh13610-fig-0004){ref-type="fig"}E). The pattern was similar in patients with and without transfusion need, i.e. the production or not of erythrocytes did not influence the results. Furthermore, to exclude the possibility that the culture system promoted survival of mutated cells, glycophorin A was used to select GPA^+^ cells from freshly isolated BM CD34^−^ cells of 7 RARS patients carrying different *SF3B1* mutations (H662Q, K700E, N626D, E622D, K666R, T663I). allele burden in the GPA^+^ fraction was similar (41% ± 5·40SE) to the BMCD34^+^ and erythroblast D14 fractions previously evaluated (46% ± 4·09SE and 43% ±6·66SE, respectively) (Fig [4](#bjh13610-fig-0004){ref-type="fig"}F).

We finally assessed *SF3B1* allele burden in reticulocytes obtained from non‐transfused RARS subjects with stable anaemia and a median of 47% (33--70) RS of total erythroblasts. We obtained fresh blood from 4 patients (MDS 8, 12, 13, 14) and one healthy control, isolated RNA from reticulocytes and performed *SF3B1* mutational analysis using cDNA. Indeed, the mutant cDNA was expressed only in the reticulocytes from the patients and not in the control (Supplementary Figure [2](#bjh13610-fig-0002){ref-type="fig"}). The *SF3B1* allele burden was 1·5‐fold lower in reticulocytes compared to corresponding fresh CD34^+^ cells (*P = *0·017) and cells cultured for 14 days (*P = 0·033*), and 1·4‐fold lower than in freshly isolated GPA^+^ cells (*P = 0·011*). These results imply reduced differentiation of *SF3B1* mutated erythroblasts into mature erythrocytes (Fig [4](#bjh13610-fig-0004){ref-type="fig"}F).

Discussion {#bjh13610-sec-0018}
==========

To test the hypothesis that *SF3B1* mutations in RARS (Papaemmanuil *et al*, [2011](#bjh13610-bib-0034){ref-type="ref"}; Yoshida *et al*, [2011](#bjh13610-bib-0056){ref-type="ref"}) implicate mRNA abnormalities, which may alter gene function essential for erythroid maturation, we focused this study to *SF3B1* mutated RARS, RCMD‐RS and RARS‐T, with or without other candidate mutations (Papaemmanuil *et al*, [2012](#bjh13610-bib-0035){ref-type="ref"}) but identified two *SF3B1* wild type patients for comparison. We adopted a genome wide approach to evaluate the impact of *SF3B1* mutations on the transcriptome and to depict dissimilarities between RARS and NBM that could add to the understanding of the disease phenotype.

RNA sequencing of RARS BM mononuclear (Visconte *et al*, [2012](#bjh13610-bib-0052){ref-type="ref"}, [2015](#bjh13610-bib-0053){ref-type="ref"}) and CD34^+^ (Dolatshad *et al*, [2015](#bjh13610-bib-0009){ref-type="ref"}) cells was previously used to study normal bone marrow, and *SF3B1* mutated and wild type patients from different WHO subgroups showing deregulated gene expression and splicing of genes involved in iron homeostasis and mitochondrial function.

By contrast, our study is the first to specifically address aberrancies during erythroid differentiation. Aberrant splicing is thought to play a pivotal role in the pathogenetic mechanism of myeloid malignancies carrying splice factor mutations, but little is known about *SF3B1* specific gene targets in RARS pathogenesis. A preliminary report revealed 230 splicing events significantly enriched in CD34^+^ cells from *SF3B1* mutated RARS, of which 90% were caused by misrecognition of the 3′ splice site. Fifty per cent of these sites resulted in frameshift, indicating that *SF3B1* mutations simultaneously may cause detrimental consequences in many genes (Shiozawa *et al*, [2014](#bjh13610-bib-0043){ref-type="ref"}).

In the present study, we report aberrant splicing of the mitochondrial transporter *TMEM14C* and the α‐globin transcription factor *TFCP2*, both regulating erythroid gene expression and involved in haemoglobin synthesis. In particular, the skipping of 150 bases in the CP2 domain that binds the α‐globin promoter may indicate that aberrant splicing affects key genes for erythroid differentiation, suggesting a possible link between splicing and transcription regulation. Furthermore, we detected two isoforms of *TMEM14C* differentially spliced between RARS and NBM. The shorter isoform, TCONS00409016, has 14 bases missing in the 5′UTR within the predicted internal ribosome entry site (IRES). IRES elements have been shown to be important for translation of specific mRNAs during mitosis, apoptosis and hypoxia (Hellen & Sarnow, [2001](#bjh13610-bib-0015){ref-type="ref"}). Therefore, a sequence change in the 5′UTR and in the IRES element may affect the translation of *TMEM14C*, with consequences for mitochondrial function and haemoglobin synthesis (Yien *et al*, [2014](#bjh13610-bib-0055){ref-type="ref"}). Interestingly, two *SF3B1* wild type patients showed a significantly different pattern with regard to *TMEM14C* TCONS15, a finding that warrants further investigation. We suggest that the aberrant expression of genes involved in haemoglobin synthesis and the splicing of erythroid‐related genes may play a key role in the ineffective erythropoiesis of RARS. Therfore, it will be very valuable to further unravel the role of *TMEM14C* and *TFCP2* in the ineffective erythropoiesis of RARS.

Furthermore, gene expression data from RNA sequencing and TLDA revealed a marked up‐regulation of haem and haemoglobin genes, a positive enrichment of the oxidative phosphorylation pathway and a down‐regulation of ABC transporters, all essential for mitochondria to execute their functions through the different cellular compartments. These findings, together with *ABCB7* down‐regulation during erythroid differentiation of RARS CD34^+^ cells *versus* NBM (Boultwood *et al*, [2008](#bjh13610-bib-0004){ref-type="ref"}; Nikpour *et al*, [2013](#bjh13610-bib-0032){ref-type="ref"}), implicate a mitochondrial dysfunction associated with the accumulation of mitochondrial ferritin (Cazzola *et al*, [2003](#bjh13610-bib-0005){ref-type="ref"}). Haem synthesis and mitochondrial respiration are intrinsically coupled by their shared metabolic pathways and mitochondrial location in the cell. The marked up‐regulation of several haemoglobin genes in the RARS transcriptome may be viewed as a compensatory reaction to the defective terminal erythroid maturation with accumulation of iron in mitochondria instead of incorporation into haem. While haemoglobin genes were up‐regulated in RARS CD34^+^ freshly isolated progenitors, corresponding studies in NBM CD34^+^ showed that the process of differentiation‐associated haemoglobin accumulation occurred first at day 6 followed by a rapid raise in the ratio between foetal and adult haemoglobin production between day 7 and day 9 (Wojda *et al*, [2002](#bjh13610-bib-0054){ref-type="ref"}). Therefore, the early up‐regulation of haemoglobin genes observed in RARS may indicate a compromised haemoglobinization during the subsequent phases of RARS erythropoiesis. The ineffective erythropoiesis, a hallmark of RARS, depicts an erythroid defect associated with decreased erythrocytes production despite increased early erythropoiesis (Tanno & Miller, [2010](#bjh13610-bib-0046){ref-type="ref"}) and up‐regulation of haemoglobin genes.

RARS is characterized by a failure of erythroid maturation and anaemia (Corey *et al*, [2007](#bjh13610-bib-0008){ref-type="ref"}) but the exact stage of maturation at which this defect occurs is poorly understood (Hattangadi *et al*, [2011](#bjh13610-bib-0014){ref-type="ref"}). Previous investigations have described apoptotic features of RARS erythroblasts in patient biopsies (Hellstrom‐Lindberg *et al*, [1997](#bjh13610-bib-0017){ref-type="ref"}) as well as in erythroid culture systems (Tehranchi *et al*, [2003](#bjh13610-bib-0047){ref-type="ref"}, [2005a](#bjh13610-bib-0048){ref-type="ref"},[b](#bjh13610-bib-0049){ref-type="ref"}). Interestingly, this does not translate into a decreased proportion of marrow erythroid cells, but rather to erythroid expansion, indicating concomitant stimulation of erythroid proliferation and survival (Nikpour *et al*, [2013](#bjh13610-bib-0032){ref-type="ref"}). To explore at which level of differentiation anaemia develops in RARS, we followed the fate of *SF3B1* mutated BM progenitors throughout differentiation. We showed that the allele burden of *SF3B1* mutated progenitors remained stable during marrow erythroid differentiation (14 days), suggesting that *SF3B1* mutations do not inhibit growth and maturation of marrow erythroblasts, in spite of mitochondrial iron accumulation. Conversely, the decreased allele burden in reticulocytes indicates that the real threat to erythropoiesis develops during terminal differentiation to erythrocytes.

We believe that these investigations offer novel insights into the erythroid differentiation process and the mechanisms of anaemia in *SF3B1* mutated RARS, providing evidence that aberrant splicing of key genes involved in iron transport and haemoglobin synthesis may alter terminal erythroid maturation. Hence, drugs targeting this process may help to relieve the anaemia of these patients. A potential therapeutic candidate is ACE‐536, which was recently shown to target late stage erythropoiesis in a mouse model of MDS (Suragani *et al*, [2014](#bjh13610-bib-0045){ref-type="ref"}) and which preliminary study also has shown efficacy in an early phase 1 trial (Attie *et al*, [2014](#bjh13610-bib-0003){ref-type="ref"}) enrolling anaemic RARS patients.
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